top of page
.png)
Medical Journal
Use of Intravaginal Cooling to Provide Symptom Relief in Women With Vulvovaginal Candidiasis and Reduce Immunopathology in an Accompanying Mouse Model
Abstract Background Vulvovaginal candidiasis (VVC), caused primarily by Candida albicans , is treated with anti-fungal drugs, often with variable efficacy and relapses. New therapeutic strategies, including drug-free alternatives, are needed. Upon overgrowth or environmental triggers, C. albicans commensal yeast transitions into hyphae resulting in an aberrant immunopathologic neutrophil response that contributes to the characteristic signs and symptoms of vaginitis. The pur
grdirks
Jan 13, 20251 min read
Pilot Case Series of a Vaginal Cooling Device for the Treatment of Vulvovaginal Candidiasis
To determine the effectiveness and speed of symptom relief of a vaginal cooling device (VCD) in the treatment of Vulvovaginal candidiasis (VVC). VVC causes itching, burning, pain or irritation, erythema, edema, excoriation and impacts quality of life, loss of confidence and self-esteem, and difficulties with sexual relations. Standard oral and local antifungal therapy have shortcomings including delayed symptomatic relief, increased drug resistance, decreased efficacy, side e
grdirks
Dec 1, 20241 min read
Vlisse™ is a Class I Device in the European Union CE Mark Pending and a FDA Class II device pending FDA clearance.
bottom of page